Prodrug strategies to overcome poor water solubility.
暂无分享,去创建一个
[1] S. Varia,et al. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. , 1984, Journal of pharmaceutical sciences.
[2] B. D. Anderson,et al. Strategies in the design of solution-stable, water-soluble prodrugs I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids. , 1985, Journal of pharmaceutical sciences.
[3] M. Skwarczynski,et al. ON intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence‐containing bioactive peptides , 2004, Biopolymers.
[4] V. Stella. A Case for Prodrugs , 2007 .
[5] T. Shen,et al. Chemical and biological studies on indomethacin, sulindac and their analogs. , 1977, Advances in drug research.
[6] S. Roffler,et al. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. , 2003, Biochemical pharmacology.
[7] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[8] Michelle A. Schmidt,et al. To Market, To Market – 2005 , 2006 .
[9] J. Fechner,et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. , 2003, Anesthesiology.
[10] Y. Kiso,et al. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration. , 2002, Bioorganic & medicinal chemistry.
[11] G. Amidon,et al. Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. , 1985, Methods in enzymology.
[12] D. Budman,et al. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors , 1996, Cancer Chemotherapy and Pharmacology.
[13] V. J. Stella,et al. The in Vitro Enzymic Labilities of Chemically Distinct Phosphomonoester Prodrugs , 1992, Pharmaceutical Research.
[14] J. Melby,et al. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. , 1961, Metabolism: clinical and experimental.
[15] D. Fleisher,et al. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs , 1996 .
[16] V. Stella,et al. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. , 1999, Journal of pharmaceutical sciences.
[17] B. Testa. Prodrug research: futile or fertile? , 2004, Biochemical pharmacology.
[18] T. Wadsten,et al. Polymorphism of estramustine. , 1989, Journal of pharmaceutical sciences.
[19] Stella,et al. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications , 1998, Journal of pharmaceutical sciences.
[20] V. Stella,et al. Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. , 1983, Journal of pharmaceutical sciences.
[21] J. Chern,et al. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). , 1999, Journal of medicinal chemistry.
[22] N. Davies,et al. Clinical Pharmacokinetics of Sulindac , 1997, Clinical pharmacokinetics.
[23] M. Skwarczynski,et al. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. , 2003, Journal of medicinal chemistry.
[24] Tomoko Ito,et al. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. , 2003, Journal of medicinal chemistry.
[25] W. Wargin,et al. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function , 1982, Journal of Pharmacokinetics and Biopharmaceutics.
[26] J. Tack,et al. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. , 2007, International journal of pharmaceutics.
[27] L. Schacter. Etoposide phosphate: what, why, where, and how? , 1996, Seminars in oncology.
[28] C. Conover,et al. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. , 2000, Critical reviews in therapeutic drug carrier systems.
[29] T. Nevalainen,et al. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[30] Qi Gao,et al. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. , 2003, Bioorganic & medicinal chemistry letters.
[31] F. Debon,et al. Use of steroid anesthesia in surgery. , 1955, Journal of the American Medical Association.
[32] V. Stella,et al. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[33] V. Stella,et al. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. , 1999, Journal of medicinal chemistry.
[34] C. V. Pesheck,et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[35] B. D. Anderson,et al. Influence of premicellar and micellar association on the reactivity of methylprednisolone 21-hemiesters in aqueous solution. , 1983, Journal of pharmaceutical sciences.
[36] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[37] M. Butters,et al. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole , 2002 .
[38] R. Kauffman,et al. Relative bioavailability of intravenouschloramphenicol succinate and oral chloramphenicol palmitate in infants and children , 1981 .
[39] D. E. Duggan,et al. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. , 1980, Drug metabolism and disposition: the biological fate of chemicals.
[40] J. Iqbal,et al. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration. , 2006, Bioorganic & medicinal chemistry.
[41] V. Stella,et al. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD. , 1998, Journal of pharmaceutical sciences.
[42] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[43] Keith Tan,et al. The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. , 2004, British journal of clinical pharmacology.
[44] J. Fechner,et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats , 2003, European journal of anaesthesiology.
[45] V. Stella,et al. Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine. , 2007, Bioorganic & medicinal chemistry letters.
[46] J. Supko,et al. Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse , 2004, Cancer Chemotherapy and Pharmacology.
[47] R. Guthrie,et al. Safety, Tolerance and Pharmacokinetics of Intravenous Doses of the Phosphate Ester of 3‐Hydroxymethyl‐5,5‐Diphenylhydantoin: A New Prodrug of Phenytoin , 1988, Journal of clinical pharmacology.
[48] K. C. Murdock,et al. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. , 1993, Journal of medicinal chemistry.
[49] Valentino J. Stella,et al. Prodrugs : challenges and rewards , 2007 .
[50] Bernard Testa,et al. Hydrolysis in drug and prodrug metabolism : chemistry, biochemistry, and enzymology , 2003 .
[51] J. Kovach,et al. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. , 1983, Cancer research.
[52] Ronald T. Borchardt,et al. Pharmaceutical profiling in drug discovery for lead selection , 2004 .
[53] E. Furfine,et al. Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir , 2004, Antimicrobial Agents and Chemotherapy.
[54] Patrick Augustijns,et al. Characterization of fasted‐state human intestinal fluids collected from duodenum and jejunum , 2006, The Journal of pharmacy and pharmacology.
[55] B. D. Anderson,et al. Strategies in the design of solution-stable, water-soluble prodrugs III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids. , 1985, Journal of pharmaceutical sciences.
[56] Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats: Retraction , 2003 .
[57] R. Borchardt. Optimizing the "drug-like" properties of leads in drug discovery , 2006 .
[58] G. Amidon,et al. Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. , 1986, Journal of pharmaceutical sciences.
[59] Bernard,et al. Advances in Drug Research , 1964 .
[60] A. Klein-Szanto,et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. , 2003, Cancer research.
[61] V. Stella,et al. Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)(2). , 2000, Journal of pharmaceutical sciences.
[62] C. Perry,et al. Estramustine Phosphate Sodium , 1995, Drugs & aging.
[63] S. Becker,et al. Fosamprenavir: advancing HIV protease inhibitor treatment options , 2004, Expert Opinion on Pharmacotherapy.
[64] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[65] C. Koboldt,et al. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration. , 2000, Journal of medicinal chemistry.
[66] J. Singer,et al. Synthesis and in Vivo Antitumor Activity of Poly(l-glutamic acid) Conjugates of 20(S)-Camptothecin , 2003 .
[67] J. Fischer,et al. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. , 2003, Clinical pharmacokinetics.
[68] V. Stella,et al. Amino acid derivatives of dapsone as water-soluble prodrugs , 1995 .
[69] Thomas J. Raub,et al. P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.
[70] R. Schowen,et al. A Mechanistic and Kinetic Study of the E-Ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin , 2003, Pharmaceutical Research.
[71] V. Stella. Prodrugs as therapeutics , 2004 .
[72] E. Falch,et al. Allopurinol prodrugs. V. Water-soluble N-substituted (aminomethyl)benzoyloxymethyl allopurinol derivatives for parenteral or rectal delivery , 1990 .
[73] W. Plunkett,et al. Metabolism and action of fludarabine phosphate. , 1990, Seminars in oncology.
[74] B. Testa,et al. Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.
[75] O. H. Chan,et al. Evaluation of a Targeted Prodrug Strategy to Enhance Oral Absorption of Poorly Water-Soluble Compounds , 1998, Pharmaceutical Research.
[76] V. Stella,et al. Prodrugs and Parenteral Drug Delivery , 2007 .
[77] S. Varia,et al. Phenytoin prodrugs IV: Hydrolysis of various 3-(hydroxymethyl)phenytoin esters. , 1984, Journal of pharmaceutical sciences.
[78] C. Jeleazcov,et al. Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. , 2005, Anesthesia and analgesia.
[79] V. Stella. A case for prodrugs: Fosphenytoin , 1996 .
[80] B. D. Anderson,et al. Strategies in the design of solution-stable, water-soluble prodrugs II: properties of micellar prodrugs of methylprednisolone. , 1985, Journal of pharmaceutical sciences.
[81] J. Gray,et al. The parenteral toxicity of clindamycin 2-phosphate in laboratory animals. , 1974, Toxicology and applied pharmacology.
[82] Christos Reppas,et al. Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.
[83] M. Percival,et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.
[84] T. Fujiwara,et al. Development of Anti-Influenza Virus Drugs I: Improvement of Oral Absorption and In Vivo Anti-Influenza Activity of Stachyflin and Its Derivatives , 1999, Pharmaceutical Research.
[85] H. Möllmann,et al. Kinetics of methylprednisolone and its hemisuccinate ester , 1985, Clinical pharmacology and therapeutics.
[86] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[87] G. Flynn,et al. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs , 2003, Pharmaceutical Research.
[88] C. Larsen,et al. Prodrugs as drug delivery systems. XXVI: Preparation and enzymatic hydrolysis of various water-soluble amino acid esters of metronidazole , 1984 .
[89] W. Prince,et al. Pharmacokinetics of GW433908, a Prodrug of Amprenavir, in Healthy Male Volunteers , 2002, Journal of clinical pharmacology.
[90] R. Fanelli,et al. Analytical and pharmacokinetic studies on the optic isomers of oxazepam succinate half-ester. , 1972, Biochemical pharmacology.
[91] M. Salmona,et al. In vitro hydrolysis of oxazepam succinate half-ester by a stereospecific soluble esterase from different animal species. , 1974, Journal of pharmaceutical sciences.
[92] M. Shelton,et al. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. , 2006, Clinical pharmacokinetics.
[93] Y. Kiso,et al. Effect of the acyl groups on O-->N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. , 2003, Bioorganic & medicinal chemistry letters.
[94] J. Therrien,et al. A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids. , 2004, Journal of medicinal chemistry.
[95] V. Stella,et al. Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationship. , 1993, Journal of pharmaceutical sciences.
[96] Richard B Greenwald,et al. Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.
[97] J. Leppänen,et al. Synthesis of a water-soluble prodrug of entacapone. , 2000, Bioorganic & medicinal chemistry letters.
[98] AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics. , 2005, Anesthesiology.
[99] R. Corradino,et al. ABSORPTION, METABOLISM, AND EXCRETION OF OXAZEPAM AND ITS SUCCINATE HALF-ESTER. , 1964, Journal of pharmaceutical sciences.
[100] R. Moss,et al. Propofol Phosphate, a Water-Soluble Propofol Prodrug:In Vivo Evaluation , 2002, Anesthesia and analgesia.
[101] Terry R Stouch,et al. Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.
[102] Tycho Heimbach,et al. Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery , 2007 .
[103] F. Abramson,et al. Bioavailability, distribution and pharmacokinetics of diethystilbestrol produced from stilphostrol. , 1982, The Journal of urology.
[104] Y. Rojanasakul,et al. Experimental and Computational Studies of Epithelial Transport of Mefenamic Acid Ester Prodrugs , 2005, Pharmaceutical Research.
[105] S. Varia,et al. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. , 1984, Journal of pharmaceutical sciences.
[106] V. Stella,et al. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs. , 1999, Journal of pharmaceutical sciences.
[107] S. Varia,et al. Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. , 1984, Journal of pharmaceutical sciences.
[108] R. Scott,et al. The Entropy of Solution of Nonelectrolytes , 1952 .
[109] B. Ruggeri,et al. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clini , 2003, Journal of medicinal chemistry.
[110] H. Möllmann,et al. Comparative Pharmacokinetics of Methylprednisolone Phosphate and Hemisuccinate in High Doses , 1988, Pharmaceutical Research.
[111] Sevtap Arikan,et al. Ravuconazole Eisai/Bristol-Myers Squibb. , 2002, Current opinion in investigational drugs.
[112] F. Schabel,et al. Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine , 1977 .
[113] L. Sorbera,et al. Valdecoxib and Parecoxib Sodium , 2001 .
[114] A. Burstein,et al. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats , 1999, Epilepsy Research.
[115] Michael J. Hageman,et al. Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization , 2006 .